In 2025, IPC advanced the priorities outlined in our strategic plan, strengthening research collaboration, expanding regional education, and progressing focused clinical initiatives that address real-world gaps in psoriasis care. This encompassed ongoing efforts in disease severity reclassification, defining topical failure, examining cardiometabolic impacts on psoriasis, addressing complex clinical scenarios, commencing development of a comprehensive textbook on psoriasis, and delivering continued regional education via our Masterclasses.
Throughout the year, our Board Members, Councilors, and Jr. Councilors led scientific discussions, educational programming, and collaborative initiatives that reflect IPC’s role as a global network of physician experts. From international symposia to clinical guidance efforts, these contributions continue to shape how psoriasis care evolves across regions.
We are grateful to the many individuals and partners who volunteer their time, expertise, and leadership to IPC’s work. Their contributions are reflected throughout the progress summarized in this report.
We invite you to view the Annual Report below to learn more about IPC’s work in 2025.
Thank you for your continued engagement and partnership
Bruce Strober, MD, PhD
President
Christy Langan
Chief Executive Officer
A new IPC paper in JAAD presents five priorities for improving metabolic screening, advancing GLP-1 research in the context of psoriasis, and defining the dermatologist’s role in managing cardiometabolic risk in psoriasis patients.
IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality disorder, shape clinical interactions and shares practical strategies for dermatologists to build stronger patient relationships.
Recordings from the IPC Fellows Research Class #1: Global and Collaborative Research in Psoriasis are now available. Program Chairs Peter van de Kerkhof, MD, PhD, and María Julia Cura, MD, led a faculty of international experts through sessions on unresolved questions in the era of effective psoriasis therapies, building global research collaborations, and connecting psoriasis research across disciplines. Watch to hear from Wolf Henning Boehncke, MD, MA, Christopher Griffiths, OBE, MD, FMedSci, and Georg Stingl, MD, as they share perspectives shaping the next generation of psoriasis research.
The IPC Resource Library now includes a dedicated Research Skills category, bringing together videos, articles, and presentations focused on building stronger research capabilities in psoriasis. Browse the current collection to find resources on topics from collaborative research methods to career development for researchers at every stage.
Rare ADAR1 gene mutations drive a distinct, interferon-fueled psoriasis subtype, and it responds to JAK1 and TYK2 inhibitors rather than standard IL-17/IL-23 biologics.
IPC Councilor Anna Lopez Ferrer, MD, PhD, reviews PURE-4, a four-item tool that helps dermatologists screen psoriasis patients for psoriatic arthritis (PsA) risk. She traces its evolution across three studies (2018–2026) into a validated predictor of early PsA.
IPC Councilor André Lucas Ribeiro, MD, reframes PsA as a slow transition from psoriasis, not a sudden event, opening the door to disease interception. He outlines the steps needed to get there, from harmonizing definitions to reducing inflammatory burden.
